Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Estimating the Cost-of-Illness Associated with the COVID-19 Outbreak in China from January to March 2020
35 Pages Posted: 12 Jun 2020More...
Background: COVID-19, an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), swept through China in 2019-2020, with over 80,000 confirmed cases reported by end of March 2020. This study estimates the economic burden of COVID-19 in 31 provincial-level administrative regions in China between January and March 2020.
Methods: The healthcare and societal cost of COVID-19 was estimated using bottom-up approach. The main cost components included identification, diagnosis and treatment of COVID-19, compulsory quarantine and productivity losses for all affected residents in China during the study period. Input data were obtained from government reports, clinical guidelines, and other published literature. The primary outcomes were total health and societal costs. Costs were reported in both RMB and USD (2019 value).
Outcomes: The total estimated healthcare and societal cost associated with the outbreak is 4·26 billion RMB (0·62 billion USD) and 2,647 billion RMB (383 billion USD), respectively. The main components of routine healthcare costs are inpatient care (41·0%) and medicines (30·9%). The main component of societal costs is productivity losses (99·8%). Hubei province incurred the highest healthcare cost (83·2%) whilst Guangdong province incurred the highest societal cost (14·6%).
Interpretation: This review highlights a large economic burden of the recent COVID-19 outbreak in China. These findings will aid policy makers in making informed decisions about prevention and control measures for COVID-19.
Funding Statement: The author(s) received no financial support for the research, authorship, and/or publication of this article.
Declaration of Interests: No funding was received for this research work. XL was an employee of GSK vaccines till 31st August 2017. MP received personal fees from Merck, outside the submitted work. Other than these, the authors declare no competing interests.
Keywords: COVID-19; SARS-CoV-2; Cost-of-illness; Economic burden; Healthcare cost; Societal cost; Productivity loss
Suggested Citation: Suggested Citation